Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05059626 · ClinicalTrials.gov registry record · Phase 4
Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee
A Phase 4 study of Endometriosis, sponsored by Penn State University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT05059626: Recruiting Phase 4 study of Endometriosis, sponsored by Penn State University.
NCT05059626 is a Phase 4 study of Endometriosis that is actively recruiting participants, run by Penn State University. The registered enrollment target is 28 participants, below the 264-participant average among 48 other Endometriosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05059626, a Phase 4 study of Endometriosis, is actively recruiting participants, sponsored by Penn State University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose: To determine the effects of SERM and simvastatin interventions on endothelial dysfunction in women with endometriosis. Hypothesis: Treatment with the SERM (bazedoxifene + conjugated estrogen) or with simvastatin will decrease systemic inflammation and improve specific measures of cardiovascular function including endothelium-dependent vasodilation.
Conditions Studied
Interventions
- DRUG simvastatin 10mg
- DRUG Bazedoxifene 20/Estrogens,Con 0.45Mg Tb
Study Locations (1)
Connecticut
- The John B. Pierce Laboratory - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-12-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT05059626 shows while recruiting
NCT05059626 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 264-participant average among 48 other Endometriosis trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 2 interventions - of which simvastatin 10mg is the first listed.
NCT05059626 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05059626 about?
NCT05059626 is a clinical study titled "Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee". Purpose: To determine the effects of SERM and simvastatin interventions on endothelial dysfunction in women with endometriosis. Hypothesis: Treatment with the SERM (bazedoxifene + conjugated estrogen) or with simvastatin will decrease systemic inflammation and improve specific measures of cardiovas...
What is the current status of trial NCT05059626?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2023-12-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05059626 study?
This clinical trial studies the following conditions: Endometriosis.
What interventions are being tested in trial NCT05059626?
The interventions under investigation include: simvastatin 10mg (DRUG), Bazedoxifene 20/Estrogens,Con 0.45Mg Tb (DRUG).
Who is sponsoring clinical trial NCT05059626?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05059626 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometriosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05059626's enrollment target sits among peer trials
28 44th of 48 higher than 5 of 48 other Endometriosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometriosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Thromboxane Function in Women With Endometriosis
RECRUITING · Phase 4
-
Superior Hypogastric Nerve Plexus Block With Bupivacaine After Robotic Resection of Endometriosis
RECRUITING · Phase 4
-
The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery
ACTIVE NOT RECRUITING · Phase 4
-
Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
COMPLETED · Phase 4
-
Supplementation in Adolescent Girls With Endometriosis
COMPLETED · Phase 4
-
Interdisciplinary Group Care for the Treatment of Endometriosis-associated Pain
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI